BAM
LAB icon

Belpointe Asset Management’s Standard BioTools LAB Stock Holding History

Belpointe Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$3.9K – 2100
2023
Q1 		$3.9K Hold
2,000
– – ﹤0.01% 3100
2022
Q4 		$2.34K Buy
+2,000
New +$2.46K ﹤0.01% 3212

Other funds holding LAB

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Belpointe Asset Management's LAB Position: Q2 2023 in Review

Belpointe Asset Management sold out of Standard BioTools (LAB) in Q2 2023, closing a stake of 2,000 shares — an estimated $3.9K sold.

Belpointe Asset Management first reported a position in LAB in Q4 2022 and held it in 2 quarters. The position peaked at $3.9K in Q1 2023. 66 funds tracked by Wall St. Rank hold LAB as of Q2 2023.

  • Belpointe Asset Management reported no remaining Standard BioTools position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,000 Standard BioTools shares in Q2 2023, an estimated $3.9K.
  • Belpointe Asset Management first reported a position in Standard BioTools in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Standard BioTools position peaked at $3.9K in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.